If you would like to join our Early Access Programme, please contact us.

It is of utmost importance to us that our products make healthworkers’ jobs easier: our technologies should be quick and simple to use.

We believe this is crucial in delivering diagnostic tools you can rely on.

To support this, QuantuMDx works with healthcare professionals from a range of settings to ensure our products fit seamlessly into clinical care pathways, and meet the needs and preferences of our end users.

Our first commercial assay will detect and individually identify 14 high-risk human papillomavirus (hr-HPV) genotypes, providing a powerful diagnostics and surveillance tool for clinicians and public health officials alike.

In advance of commercialisation, we’re looking to collaborate with a small cohort of key partners to support our Q-POC™ clinical validation and implementation programme.

If your healthcare organisation is interested in taking part in our Early Access programme, please use the Contact page to get in touch with our Business Development team.

Subscribe to our e-newsletter and keep up to date with QuantuMDx